Tirzepatide is a once-weekly injectable medication. In the U.S., it’s marketed as:

• Treatment for type 2 diabetes (Under strict doctor supervision)

• Treatment for chronic weight management (obesity / overweight with a weight-related condition)

 

It’s known as a dual incretin agonist because it activates two hormone receptors:

• GLP-1 receptor

• GIP receptor

 

How it works (in plain English)

1) GLP-1 action

• Turns down appetite and helps you feel full sooner

• Slows stomach emptying (food moves through more slowly)

• Improves blood sugar control by increasing insulin release when glucose is high

2) GIP action

• Helps the body handle post-meal glucose better (glucose-dependent insulin effects)

• Works in combination with GLP-1 to improve metabolic control and contributes to the overall weight/glucose effects

Net effect: in FDA labeling, tirzepatide is described as lowering fasting/post-meal glucose, decreasing food intake, and reducing body weight.

 

What studies have shown so far

• In the SURMOUNT-1 trial (72 weeks, adults with obesity without diabetes), once-weekly tirzepatide produced substantial, sustained weight loss vs placebo across doses (5/10/15 mg).

• In a head-to-head trial vs semaglutide in adults with obesity (without diabetes), tirzepatide showed greater average weight reduction at 72 weeks.

​​

What are these dual weight management agonists?

​

1) GLP-1 receptor action (Glucagon-Like Peptide-1)

What it mainly does

• Appetite + satiety: GLP-1 is a normal body signal involved in appetite and caloric intake; activating it helps people feel full sooner and stay full longer.

• Stomach emptying: It can slow gastric emptying, which blunts big hunger swings and can reduce post-meal glucose spikes (especially early in treatment).

• Glucose control: Supports glucose lowering by improving insulin response when glucose is elevated (part of incretin physiology).

 

What you might notice day-to-day

• Less “food noise,” smaller portions, fewer cravings

• Feeling “full” sooner than expected

• Early on: nausea/fullness, especially around dose increases (common class pattern)

 

Why it matters in tirzepatide

GLP-1 is the “foundation” appetite lever that many people already know from semaglutide—tirzepatide includes it, but adds GIP to change the total effect.

 

2) GIP receptor action (Glucose-Dependent Insulinotropic Polypeptide)

What it mainly does

• Enhances insulin secretion (glucose-dependent): GIP is a native incretin hormone that helps the pancreas release insulin in response to food, and tirzepatide activates that pathway.

• Improves insulin sensitivity: Clinical pharmacology descriptions and reviews note improvements in insulin sensitivity/insulin secretory responses with tirzepatide.

• Adds to food-intake regulation: Lilly’s labeling explicitly notes GLP-1 regulates appetite/caloric intake and that adding GIP may further contribute to regulation of food intake.

 

What you might notice day-to-day

• Better post-meal stability (less “crash” feeling for some people)

• In type 2 diabetes: often better A1c/post-meal control than GLP-1 alone (trial-program pattern)

• Potentially different tolerability feel vs GLP-1-only meds (varies person to person)

 

Why it matters in tirzepatide

This is the “extra engine.” Tirzepatide is one molecule that activates both GIP and GLP-1 receptors, and the combo is believed to drive its strong glucose + weight effects.

Putting them together (why the combo tends to be potent)

 

A simple mental model:

• GLP-1: “Eat less (satiety), slow digestion”

• GIP: “Handle nutrients better (insulin response/sensitivity) and may further help appetite regulation”

In obesity trials, this dual action translated into substantial, sustained weight loss at 72 weeks in SURMOUNT-1